127 results on '"Scheffold C"'
Search Results
2. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
3. Hochdosistherapie und Stammzelltransplantation
4. TBI-Based Reduced Intensity Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) in Patients with High-Risk Hematologic Malignancies
5. CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich zu Sunitinib bei fortgeschrittenem Nierenzellkarzinom - aktualisierte Ergebnisse mit verlängerter Nachbeobachtung und bei sarkomatoider Histologie
6. Influence of the factor II G20210A variant or the factor V G1691A mutation on symptomatic recurrent venous thromboembolism in children: an international multicenter cohort study
7. CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich zu Sunitinib bei fortgeschrittenem Nierenzellkarzinom - aktualisierte Ergebnisse mit verlängerter Nachbeobachtung und bei sarkomatoider Histologie
8. Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells
9. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab
10. XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile
11. P1751 Right ventricular dysfunction in heart failure patients with reduced ejection fraction with and without chronic respiratory diseases: A treacherous combination for the ominous outcome?
12. P904 Impact of significant functional mitral regurgitation and aortic stenosis on outcome of HFrEF patients
13. 161 Impact of right ventricular dysfunction on outcome in heart failure patients with mid-range ejection fraction with and without chronic respiratory diseases
14. Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis
15. TBI 8 Gy / fludarabine as conditioning for allogeneic HSCT from related or unrelated donors in AML: improved benefit risk ratio for patients in first or second complete remission (CR1/CR2)
16. Constitutive activation of the phosphatidylinositol 3-kinase/AKT pathway in acute myeloid leukemia and mTOR-inhibition by rapamycin: P629
17. Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group
18. High remisssion rate in patients with advanced chronic lymphocytic leukemia after reduced intensity conditioning and allogeneic stem cell transplantation: 606
19. Allogeneic cellular immunotherapy for the treatment of malignant melanoma: 405
20. METEOR Studie: Retrospektive Analyse von Patienten mit fortgeschrittenem Nierenzellkarzinom bezüglich der Wirksamkeit von Cabozantinib (CABO) vs Everolimus (EVE) in Abhängigkeit vom Nephrektomiestatus
21. P4513Impact of right ventricular dysfunction on outcome in heart failure patients with mid-range ejection fraction with and without chronic respiratory diseases
22. P3551Right ventricular dysfunction in heart failure patients with reduced ejection fraction with and without chronic respiratory diseases: A treacherous combination for the ominous outcome?
23. Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)
24. Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
25. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
26. Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)
27. Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
28. Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
29. 872P - Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)
30. 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
31. LBA38 - Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
32. 872P - Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
33. 2117 - Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)
34. O4 - Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
35. Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia
36. 816P - Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
37. Mode Equivalence of Interactive Voice Response (IVR) and Paper Versions of the Brief Pain Inventory (BPI) “Worst Pain” Item in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Evaluated Conceptually Using Qualitative Methods
38. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
39. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.
40. 397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)
41. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.
42. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
43. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
44. 218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
45. PRM147 - Mode Equivalence of Interactive Voice Response (IVR) and Paper Versions of the Brief Pain Inventory (BPI) “Worst Pain” Item in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Evaluated Conceptually Using Qualitative Methods
46. Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells.
47. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells
48. Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+donor cell chimerism analysis.
49. PRM147 Mode Equivalence of Interactive Voice Response (IVR) and Paper Versions of the Brief Pain Inventory (BPI) 'Worst Pain' Item in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Evaluated Conceptually Using Qualitative Methods
50. 33 Poster Discussion - XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.